^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    α2 adrenergic receptor antagonist

    Related drugs:
    2d
    Efficacy and Mechanism of IPSRT for Bipolar II Disorder (clinicaltrials.gov)
    P2, N=216, Not yet recruiting, First Affiliated Hospital of Zhejiang University
    New P2 trial
    1m
    The Tina Trial: A trial of mirtazapine for methamphetamine dependence (ACTRN12622000235707)
    P3, N=340, Completed, University of New South Wales | Active, not recruiting --> Completed
    Trial completion
    2ms
    TQDelirium: Trazodone vs. Quetiapine for the Treatment of ICU Delirium (clinicaltrials.gov)
    P=N/A, N=10, Terminated, University of Southern California | N=60 --> 10 | Recruiting --> Terminated; PI left institution. No one resumed the project.
    Enrollment change • Trial termination
    2ms
    RCT: Trazodone vs Quetiapine vs Placebo for Treating ICU Delirium (TraQ) (clinicaltrials.gov)
    P4, N=0, Withdrawn, University of Southern California | N=30 --> 0 | Trial completion date: Dec 2026 --> Dec 2030 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jul 2026 --> Jul 2029
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    2ms
    In silico analysis of gene expression signatures and drug repurposing associated with metastatic progression in melanoma (skin cancer). (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
    Virtual screening results show repurposable compounds, with Floxacrine showing strong predicted affinity for CUL5 and Dihydroergocristine showing favorable interaction with LPCAT2/ZC3H14-related targets...Results highlight a useful hypothesis-generating framework for biomarker prioritization and drug repurposing in melanoma. However, independent cohort validation and experimental confirmation are required before clinical translation.
    Journal
    |
    HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • LPCAT2 (Lysophosphatidylcholine Acyltransferase 2)
    2ms
    A single centre pilot randomised controlled trial of enteral Guanfacine vs Quetiapine for agitated delirium in patients in the intensive care unit (ACTRN12624001075572)
    P2, N=36, Terminated, Austin Hospital | Recruiting --> Terminated
    Trial termination
    3ms
    A Study of Idazoxan in Healthy Participants (clinicaltrials.gov)
    P1, N=150, Active, not recruiting, Terran Biosciences Australia Pty Ltd | Recruiting --> Active, not recruiting | Trial completion date: Mar 2024 --> Dec 2027 | Trial primary completion date: Mar 2024 --> Dec 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    3ms
    VEGA-3: Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia (clinicaltrials.gov)
    P3, N=569, Completed, Ocuphire Pharma, Inc. | Trial completion date: May 2026 --> Jan 2026 | Trial primary completion date: Oct 2025 --> Apr 2025 | Active, not recruiting --> Completed
    Trial completion • Trial completion date • Trial primary completion date
    3ms
    LYNX-2: Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances (clinicaltrials.gov)
    P3, N=200, Completed, Ocuphire Pharma, Inc. | Active, not recruiting --> Completed
    Trial completion
    5ms
    Effects of Mirtazapine on Appetite in Advanced Cancer Patients (clinicaltrials.gov)
    P2, N=98, Active, not recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial primary completion date
    5ms
    Mirtazapine for Acute and Chronic Post Mastectomy Pain (clinicaltrials.gov)
    P1, N=62, Completed, Assiut University | Active, not recruiting --> Completed | Trial completion date: Dec 2027 --> Dec 2025 | Trial primary completion date: Jul 2027 --> Dec 2025
    Trial completion • Trial completion date • Trial primary completion date
    6ms
    Effects of Mirtazapine on Appetite in Advanced Cancer Patients (clinicaltrials.gov)
    P2, N=98, Active, not recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Dec 2027 --> Dec 2025
    Trial primary completion date